Switchpoint Bio raises $5.3m to track treatment response through blood
Switchpoint Bio is developing blood-based epigenomic measurements to help drug developers follow biological changes during treatment.

Knowing whether a treatment helped is one question. Understanding what changed inside the body is another.
What happened
Switchpoint Bio disclosed $5.3 million in pre-seed financing, including $5 million from Treehouse Delmar Investments.
The company is developing a platform that combines blood-based DNA-methylation measurements with AI analysis. The funding supports clinical and industry validation, expanded datasets and growth of its scientific and technical team.
Why it matters
Repeated measurements can help researchers study how a patient's biology changes during treatment. Blood sampling offers a practical way to collect information over time, alongside other clinical evidence.
The bigger picture
More precise drug development needs tools for observing response as well as tools for discovering molecules. Switchpoint is building a measurement layer intended to help researchers investigate which biological mechanisms change, persist or resist treatment.
